Beta-lactamase inhibitor prodrug
View Patent ↗Prodrugs of 6-β-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention or a solvate thereof, an optional beta-lactam antibiotic and a pharmaceutically acceptable excipient. Further disclosed is a method for increasing the therapeutic effectiveness of a beta-lactam antibiotic in a mammal by administering an effective amount of a beta-lactam antibiotic and an effectiveness-increasing amount of a prodrug of the present invention, or a solvate thereof. Additionally disclosed is a method for treating a bacterial infection in a mammal by administering a therapeutically effective amount of a pharmaceutical composition of the present invention to a mammal in need thereof.
1. A compound selected from the compounds having the structure:
wherein R is H or methyl, wherein the compound may be in the form of a solvate.
2. A compound of claim 1 selected from:
(a) 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide, (2S,5R,6R)-;
(b) 4-thia-1-azabicyclo[3.2.0]heptane-2-cartoxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-(benzoyloxy)ethyl ester, 4,4-dioxide, (2S,5R,6R)-; or
(c) 4-this-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (benzoyloxy)methyl ester, 4,4-dioxide, (2S,5R,6R)-.
3. The compound of claim 1 having the structure:
which may be in the form of a solvate.
4. A composition comprising a mixture of at least (a) 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyf)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide, (2S,5R,6R)-; and (b) 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyl)-3,3-dimethyl-7-oxo-, (1S)-1-(benzoyloxy)ethyl ester, 4,4-dioxide, (2S,5R,6R)-, wherein the mixture may be in the form of a solvate.
5. A composition comprising at least one compound of claim 1 in combination with at least one beta-lactam antibiotic.
6. A composition comprising at least one compound of claim 1 in combination with amoxicillin.
7. A composition comprising the compound of claim 3 in combination with at least one beta-lactam antibiotic.
8. A pharmaceutical composition comprising at least one compound of claim 1 in combination with at least one beta-lactam antibiotic, with or without one or more pharmaceutically acceptable excipients.
9. A method of treating bacterial infection comprising administering, to a mammal in need, (1) at least one compound of claim 3 and (2) at least one beta-lactam antibiotic in amounts such that the combination of (1) and (2)is effective.
10. A method of treating bacterial infection comprising administering, to a mammal in need, (1) the compound of claim 3 and (2)-a beta-lectern antibiotic in amounts such that the combination of (1) and (2) is effective.
11. A method of treating bacterial infection comprising administering, to a mammal in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising:
(a) 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-(hydroxymethyi)-3,3-dimethyl-7-oxo-, (1R)-1-(benzoyloxy)ethyl ester, 4,4-dioxide, (2S,5R,6R)-, which may be in the form of a solvate; and
(b) a beta-lactam antibiotic.
12. A method for increasing the effectiveness of a beta-lectern antibiotic comprising administering, to a mammal in need, the beta-lactam antibiotic and an effectiveness-increasing amount of at least one compound of claim 1 .
13. A method for increasing the effectiveness of a beta-lactam antibiotic comprising administering, to a mammal in need, the beta-lactam antibiotic and an effectiveness-increasing amount of the compound of claim 3 .